- Email: [email protected]
Pasteurella multicoda immunogen and vaccine production: use in the control of atrophic rhinitis fowl cholera pasteurellosis
Patent Report Viruses having recombinant surface proteins: preparation and use in forming improved and safer viral vaccines
Pasteurella multicoda immunogen and vaccine production: use in the control of atrophic rhinitis fowl cholera pasteurellosis
Animal Vaccine Rex Corp. World 8302-393:21 July 1983
Duphar Eur. 85--469; 10 August 1983
Reproductively viable virus having a foreign nucleotide base sequence inserted in its genome, the sequence expressing itself as a biologically active segment of a surface protein of the virus is new. The viral carriers are useful for inducing immune responses in animals to give improved and safer vaccines for use. The usual recombinant DNA techniques are used in the construction of the modified viruses. Suitably a surface viral protein (or a portion of it) that is not critical to the reproductive viability of the virus is determined and the foreign nucleotide base sequence is inserted into the viral genome at a location where the sequence expresses itself as an exposed segment of the non-critical surface. The vector is used to transfect an organism and hence multiple copies of the vector are obtained. 006-84
Preparation of an immunogen comprises culturing a Pasteurella multicoda strain, either Carter D-type, Carter Atype or USA standard type 3, P-1059, for 12 to 24 h in liquid medium. Cultivation is at 37°C in brain-heart-infusion medium. The bacteria are then removed from the medium and the filtrate is sterile-filtered and rapidly frozen or freezedried. Preparation of a vaccine against P. multicoda infections comprises of converting the immunogen into a form suitable for administration. An adjuvant and/or other active components may be added. The vaccines may be used for control of atrophic rhinitis in pigs, fowl cholera, hemorrhagic septicemia in cattle, and pasteurella infections in sheep, cattle, pigs, and rabbits. The freeze-dried immunogen is relatively stable. 009-84
Vaccines against bluetongue virus - - containing attenuated virus Tex A & M Univ. System World 8302-394:21 July 1983 Vaccines for immunizing ruminants against bluetongue virus (BTV) serotypes IT 10, 11, 13 and 17 comprise at least 10 000 tissue culture infectious doses of 1 or more of these serotypes/ml. Attenuation may be effected by 30 or more serial passages through Vero cell cultures in a nutrient medium at 30-36°C, with each passage lasting 2-7 days. A sample of live virulent BTV IT 11 strain was obtained from blood cells which were disrupted in a tissue grinder and diluted with PBS. A sample of the lysed suspension was added to a decanted monolayer of Vero cells and allowed to adsorb at 30-34°C for 1 h in tubes. Maintenance medium of Basal Medium Eagle (BME) in HBSS supplemented with horse serum, tryptose phosphate broth, penicillin and streptomycin was added and the tubes were incubated at 30-34°C. In each passage the CPE was allowed to develop until 75% or more of the monolayer was destroyed. The samples were rapidly frozen at -85°C. The tube contents were harvested and subjected to 30-50 additional identical pasages. (X)7-84
Vaccine against porcine respiratory disease - - containing inactivated and adsorbed cultures of Haemophylus pleuropneumoniae, Pasteurella multocida and Bordetella bronchiseptica Inst Cercet Vet Bioprep. Pasteur Romanian 80-305; 30 November 1982 A vaccine against some respiratory diseases in pigs consists of a combination of 40% inactivated and adsorbed culture of Haemophylus pleuropneumoniae No. 497 and 887/1980 of the collection of the Pasteur Institute of Veterinary Research and Bio-preparations, Bucharest, brain heart infusion, NAD, normal horse serum and liquid beer yeast extract; 30% inactivated and adsorbed culture ofPasteurella multocida No. 511 and 616 of the same collection, tryptonated water or peptonated water, glucose, extract of weaned calf heart. Martin peptone, liquid beer yeast extract, and 30% inactivated and adsorbed culture of Bordetella bronchiseptica No. 68 and 93 of the same collection, extract of weaned calf and Martin peptone, glucose, liquid beer yeast extract, formol and AI(OH)2. 010-84
Plnsmids coding for enterotoxoid production: EscheHchia coil transformation and expression of enterotoxoid in high yield for vaccine preparation
Vaccines for immunization of mammals: contain ozone inactivated pathogenic microorganism and carrier
Sandoz World 8302-456:21 July 1983
Regents-Univ. Calif. Eur. 86--071; 17 August 1983
Plasmids pEFK600, pEFKT00, pEFK800 and pEBK620 are new. pEFK600 is .produced by cleaving pEFK295 with HindllI, ligating with T4-1igase, using the resulting DNA to transform Escherichia coli K12 5K, identifying enterotoxoidproducing clones, and isolating a recombinant plasmid containing a 2.8 kb gene fragment ofplasmid P307. Plasmid pEFK700 i_s p.roduced by cleaving P307 and pHUB2 with BamHl, ligating, transforming E. coli K12 5K cells containing plasmid pRK248clts and isolating a plasmid containing an 8.78 kb fragment of P307 from transformants. Plasmid pEFKS00 is produced by cleaving pEFK700 with EcoRI, ligating and transformingE, coli KI 2 5K/pRK248clts and isolating pEFK800 from transformants. Plasmid pEBK620 is produced by cleaving pEFK295 with Hindlil. cleaving pKSI00 with HindllI and treating with alkalinephoshatase, ligating, transforming E. coil K12 165-delta(gas)-trp, and isolating a recombinant plasmid from transformants. 008-84
A vaccine for immunization ofa mamm,!ian host comprises an ozone-inactivated pathogenic microorganism in a physiologically acceptable carrier. The inactivated microorganisms in the carrier activated the immune system to protect the host from infection by microorganisms. The inactivation can be effected without significant modification or morphology. Ozone was generated in medical grade oxygen by silent electric arc discharge. An apparatus containing an ozone exposure vessel and a control vessel and ultrafilters, etc. was used. Influenza A virus was propagated at 37°C in monolayers of susceptible cells grown in roller culture in Eagles minimal essential medium (MEM) etc. containing gentamycin. Hepes buffer and fetal calf serum. The infected ceils and supernatant were centrifuged. The virus was grown in MadinDarby bovine kidney (MDBK) cells infected and incubated for 27 h. Aliquots of virus suspension in glass roller culture bottles were rotated at 37°C while humidified gas containing ozone passed through for 72 h. 011-84
108
Vaccine, Vol. 2, March 1984
Pasteurella multicoda immunogen and vaccine production: use in the control of atrophic rhinitis fowl cholera pasteurellosis
Animal Vaccine Rex Corp. World 8302-393:21 July 1983
Duphar Eur. 85--469; 10 August 1983
Reproductively viable virus having a foreign nucleotide base sequence inserted in its genome, the sequence expressing itself as a biologically active segment of a surface protein of the virus is new. The viral carriers are useful for inducing immune responses in animals to give improved and safer vaccines for use. The usual recombinant DNA techniques are used in the construction of the modified viruses. Suitably a surface viral protein (or a portion of it) that is not critical to the reproductive viability of the virus is determined and the foreign nucleotide base sequence is inserted into the viral genome at a location where the sequence expresses itself as an exposed segment of the non-critical surface. The vector is used to transfect an organism and hence multiple copies of the vector are obtained. 006-84
Preparation of an immunogen comprises culturing a Pasteurella multicoda strain, either Carter D-type, Carter Atype or USA standard type 3, P-1059, for 12 to 24 h in liquid medium. Cultivation is at 37°C in brain-heart-infusion medium. The bacteria are then removed from the medium and the filtrate is sterile-filtered and rapidly frozen or freezedried. Preparation of a vaccine against P. multicoda infections comprises of converting the immunogen into a form suitable for administration. An adjuvant and/or other active components may be added. The vaccines may be used for control of atrophic rhinitis in pigs, fowl cholera, hemorrhagic septicemia in cattle, and pasteurella infections in sheep, cattle, pigs, and rabbits. The freeze-dried immunogen is relatively stable. 009-84
Vaccines against bluetongue virus - - containing attenuated virus Tex A & M Univ. System World 8302-394:21 July 1983 Vaccines for immunizing ruminants against bluetongue virus (BTV) serotypes IT 10, 11, 13 and 17 comprise at least 10 000 tissue culture infectious doses of 1 or more of these serotypes/ml. Attenuation may be effected by 30 or more serial passages through Vero cell cultures in a nutrient medium at 30-36°C, with each passage lasting 2-7 days. A sample of live virulent BTV IT 11 strain was obtained from blood cells which were disrupted in a tissue grinder and diluted with PBS. A sample of the lysed suspension was added to a decanted monolayer of Vero cells and allowed to adsorb at 30-34°C for 1 h in tubes. Maintenance medium of Basal Medium Eagle (BME) in HBSS supplemented with horse serum, tryptose phosphate broth, penicillin and streptomycin was added and the tubes were incubated at 30-34°C. In each passage the CPE was allowed to develop until 75% or more of the monolayer was destroyed. The samples were rapidly frozen at -85°C. The tube contents were harvested and subjected to 30-50 additional identical pasages. (X)7-84
Vaccine against porcine respiratory disease - - containing inactivated and adsorbed cultures of Haemophylus pleuropneumoniae, Pasteurella multocida and Bordetella bronchiseptica Inst Cercet Vet Bioprep. Pasteur Romanian 80-305; 30 November 1982 A vaccine against some respiratory diseases in pigs consists of a combination of 40% inactivated and adsorbed culture of Haemophylus pleuropneumoniae No. 497 and 887/1980 of the collection of the Pasteur Institute of Veterinary Research and Bio-preparations, Bucharest, brain heart infusion, NAD, normal horse serum and liquid beer yeast extract; 30% inactivated and adsorbed culture ofPasteurella multocida No. 511 and 616 of the same collection, tryptonated water or peptonated water, glucose, extract of weaned calf heart. Martin peptone, liquid beer yeast extract, and 30% inactivated and adsorbed culture of Bordetella bronchiseptica No. 68 and 93 of the same collection, extract of weaned calf and Martin peptone, glucose, liquid beer yeast extract, formol and AI(OH)2. 010-84
Plnsmids coding for enterotoxoid production: EscheHchia coil transformation and expression of enterotoxoid in high yield for vaccine preparation
Vaccines for immunization of mammals: contain ozone inactivated pathogenic microorganism and carrier
Sandoz World 8302-456:21 July 1983
Regents-Univ. Calif. Eur. 86--071; 17 August 1983
Plasmids pEFK600, pEFKT00, pEFK800 and pEBK620 are new. pEFK600 is .produced by cleaving pEFK295 with HindllI, ligating with T4-1igase, using the resulting DNA to transform Escherichia coli K12 5K, identifying enterotoxoidproducing clones, and isolating a recombinant plasmid containing a 2.8 kb gene fragment ofplasmid P307. Plasmid pEFK700 i_s p.roduced by cleaving P307 and pHUB2 with BamHl, ligating, transforming E. coli K12 5K cells containing plasmid pRK248clts and isolating a plasmid containing an 8.78 kb fragment of P307 from transformants. Plasmid pEFKS00 is produced by cleaving pEFK700 with EcoRI, ligating and transformingE, coli KI 2 5K/pRK248clts and isolating pEFK800 from transformants. Plasmid pEBK620 is produced by cleaving pEFK295 with Hindlil. cleaving pKSI00 with HindllI and treating with alkalinephoshatase, ligating, transforming E. coil K12 165-delta(gas)-trp, and isolating a recombinant plasmid from transformants. 008-84
A vaccine for immunization ofa mamm,!ian host comprises an ozone-inactivated pathogenic microorganism in a physiologically acceptable carrier. The inactivated microorganisms in the carrier activated the immune system to protect the host from infection by microorganisms. The inactivation can be effected without significant modification or morphology. Ozone was generated in medical grade oxygen by silent electric arc discharge. An apparatus containing an ozone exposure vessel and a control vessel and ultrafilters, etc. was used. Influenza A virus was propagated at 37°C in monolayers of susceptible cells grown in roller culture in Eagles minimal essential medium (MEM) etc. containing gentamycin. Hepes buffer and fetal calf serum. The infected ceils and supernatant were centrifuged. The virus was grown in MadinDarby bovine kidney (MDBK) cells infected and incubated for 27 h. Aliquots of virus suspension in glass roller culture bottles were rotated at 37°C while humidified gas containing ozone passed through for 72 h. 011-84
108
Vaccine, Vol. 2, March 1984